<DOC>
	<DOCNO>NCT00927511</DOCNO>
	<brief_summary>In post-menopausal metastatic hormone-responsive breast cancer woman . This study two arm randomize trial evaluate effectiveness dose-titration regimen fulvestrant compare approve dose regimen . Patients randomize one follow treatment arm : Arm A : Fulvestrant 500 mg day 0 , 14 , 28 , 250 mg every 2 week 5 administration , 250 mg every 28 day , progression unacceptable toxicity Arm B : Fulvestrant 250 mg every 28 day progression unacceptable toxicity</brief_summary>
	<brief_title>A Study , Comparing Dose-Titration Regimen Fulvestrant With Approved Dosing Regimen Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer ( ABC )</brief_title>
	<detailed_description>Arm A : Fulvestrant 500 mg day 0 , 14 , 28 , 250 mg every 2 week 5 administration , 250 mg every 28 day , progression unacceptable toxicity Arm B : Fulvestrant 250 mg every 28 day progression unacceptable toxicity</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Written inform consent Histological cytological diagnosis hormoneresponsive metastatic breast cancer Documented positive hormone receptor status ( ER+ve and/or PgR+ve ) primary metastatic tumor issue , accord local laboratory parameter Postmenopausal woman , define woman fulfil 1 follow criterion : Age ≥ 60 year Age ≥ 45 year amenorrhoea ≥ 12 month intact uterus Having undergone bilateral oophorectomy FSH oestradiol level postmenopausal range ( utilizing range local laboratory facility ) * *In patient previously treat monthly LHRH analogue , last depot must administer 13 month ( 15 month case 3monthly LHRH analogue ) prior randomization , menses must restart Prior hormonal treatment adjuvant setting allow No one prior hormonal treatment metastatic disease Patients HER2 positive disease treatment specific antiHER2 therapy ( trastuzumab , lapatinib ) allow ECOG performance status 02 Patients fulfil one follow criterion : Patients measurable disease per RECIST criterion . This define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Patients bone lesion , lytic mixed ( lytic + sclerotic ) , absence measurable disease define RECIST criterion . Bone lesion must evaluable plain Xray , CT MRI . Patients lesion identify radionucleotide bone scan eligible Patients history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence . Patients follow cancer eligible diagnose treat within past 5 year : cervical carcinoma situ , melanoma situ , basal cell squamous cell carcinoma skin Patients must normal organ function define : total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) 2.5 X institutional upper limit normal creatinine within normal institutional limit creatinine clearance 0.60 mL/min/1.73 m2 patient creatinine level institutional normal Receive concurrent treatment investigational agent participate another clinical trial Have concurrent disease condition would make patient inappropriate study participation , serious medical disorder would interfere patient safety Patients responsive stable disease chemotherapy ( fulvestrant administration allow maintenance therapy ) More 1 line chemotherapy metastatic setting ; 1 maintenance hormonal therapy Life expectancy &lt; 6 month Have active uncontrolled infection Have dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent History bleeding diathesis , long term anticoagulant therapy ( antiplatelet therapy low dose warfarin ) History hypersensitivity active inactive excipients Fulvestrant</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>metastatic hormone-responsive breast cancer menopausal woman</keyword>
</DOC>